Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib-Reference-Cited by-同舟云学术

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib

Published:2014-12 Issue:12 Volume:9 Page:1821-1825
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ou Sai-Hong Ignatius,Klempner Samuel J.,Greenbowe Joel R.,Azada Michele,Schrock Alexa B.,Ali Siraj M.,Ross Jeffrey S.,Stephens Philip J.,Miller Vincent A.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014);Mok;J Clin Oncol,2014

2. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

3. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology;Ou;Oncologist,2012

4. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib;Fang;J Thorac Oncol,2014

5. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma;Hong;J Thorac Oncol,2014

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic Landscape of NSCLC in the Republic of Ireland;JTO Clinical and Research Reports;2024-02

2. Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report;Frontiers in Oncology;2023-08-29

3. Chromosome 7;Cancer Genes;2023-07-09

4. Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical;Molecules;2023-06-09

5. Clinical application of the AMOY 9-in-1 panel to lung cancer patients;Lung Cancer;2023-05